tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Metalidis C et al. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. 2011 Transplantation pmid:21544031
Shihab FS et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. 2008 Transplantation pmid:18475181
Ekberg H Calcineurin inhibitor sparing in renal transplantation. 2008 Transplantation pmid:18813097
Fischer L et al. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. 2015 Transplantation pmid:26151607
Shirakata Y et al. Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. 1995 Transplantation pmid:8545894
Satterthwaite R et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. 1998 Transplantation pmid:9484771
Leroy-Matheron C et al. Inhibitor against coagulation factor V after liver transplantation. 1999 Transplantation pmid:10532550
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Francavilla A et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. 1992 Transplantation pmid:1371198
Silva HT et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. 2014 Transplantation pmid:24521771
Nakamura Y et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. 2003 Transplantation pmid:12717187
Calmus Y et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. 2010 Transplantation pmid:20495510
Ouyang J et al. Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. 2005 Transplantation pmid:15912108
Egli A et al. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. 2009 Transplantation pmid:19935369
Boyer O et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. 2005 Transplantation pmid:15912111
Abbott KC et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. 2005 Transplantation pmid:16340779
Villanueva G and Baldwin D Rosiglitazone therapy of posttransplant diabetes mellitus. 2005 Transplantation pmid:16340782
Numakura K et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. 2005 Transplantation pmid:16340785
Koneru B et al. Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? 1997 Transplantation pmid:9197350
Cendales LC et al. Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. 2005 Transplantation pmid:16340790
Sugitani A et al. En bloc pancreas and kidney transplantation in a patient with limited vascular access. 1997 Transplantation pmid:9197366
Shihab FS et al. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. 2009 Transplantation pmid:19202436
Bayer ND et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. 2010 Transplantation pmid:20724958
High KP The antimicrobial activities of cyclosporine, FK506, and rapamycin. 1994 Transplantation pmid:7517076
Yoshimura N et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. 1994 Transplantation pmid:7517078
Kiuchi T et al. A hepatic graft tuberculosis transmitted from a living-related donor. 1997 Transplantation pmid:9089234
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
de Sandes-Freitas TV et al. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. 2015 Transplantation pmid:25929604
Hytiroglou P et al. FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. 1993 Transplantation pmid:7506452
Sankary HN et al. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. 1998 Transplantation pmid:9798690
Garcia-Criado FJ et al. Possible tacrolimus action mechanisms in its protector effects on ischemia-reperfusion injury. 1998 Transplantation pmid:9798713
Mack-Shipman LR et al. Reproductive hormones after pancreas transplantation. 2000 Transplantation pmid:11063337
Pirsch JD et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9112351
Sokal EM et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. 1997 Transplantation pmid:9392308
Jindal RM et al. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7519799
Newell KA et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. 1996 Transplantation pmid:8779685
Mor E et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. 1994 Transplantation pmid:7519800
Heilman RL et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. 2011 Transplantation pmid:21775930
Bellon H et al. The Effect of Immunosuppression on Airway Integrity. 2017 Transplantation pmid:28471870
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Barten MJ et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. 2004 Transplantation pmid:15114077
Uryuhara K et al. Thymectomy impairs but does not uniformly abrogate long-term acceptance of semi-identical liver allograft in inbred miniature Swine temporarily treated with FK506. 2004 Transplantation pmid:15114080
Jain A et al. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. 2000 Transplantation pmid:10653398
Gruessner RW et al. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. 1997 Transplantation pmid:9415558
Yamazaki S et al. Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. 2008 Transplantation pmid:18852671
Kiuchi T CNIs: immediate benefits but storing problems for the future? 2008 Transplantation pmid:18946338
Couzi L et al. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. 2008 Transplantation pmid:18946343
Horner BM et al. Recipient damage after musculocutaneous transplant rejection. 2008 Transplantation pmid:18946349
Stevens RB et al. A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. 2015 Transplantation pmid:25083614
Abadja F et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. 2011 Transplantation pmid:21818055
Shimada T et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. 2002 Transplantation pmid:12451243
Kaufman DB et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. 1995 Transplantation pmid:7541579
Herzog D et al. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. 2006 Transplantation pmid:16534467
Tanaka A et al. Living related liver transplantation across ABO blood groups. 1994 Transplantation pmid:7522363
McDiarmid SV et al. Factors affecting growth after pediatric liver transplantation. 1999 Transplantation pmid:10030286
Eckhoff DE et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. 2000 Transplantation pmid:10830224
Nakata Y et al. Tacrolimus and myocardial hypertrophy. 2000 Transplantation pmid:10830241
Hanto DW and Chudzinski R What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? 2009 Transplantation pmid:19155968
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Schena FP et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. 2009 Transplantation pmid:19155978
Opelz G and Döhler B Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. 2008 Transplantation pmid:18698238
Gouraud A et al. Follow-up of tacrolimus breastfed babies. 2012 Transplantation pmid:22996303
Apanay DC et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. 1994 Transplantation pmid:7524202
Steinmüller TM et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. 1994 Transplantation pmid:7524203
Singh N et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. 1994 Transplantation pmid:7524204
Roberti I et al. Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. 1992 Transplantation pmid:1384182
Langrehr JM et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. 1992 Transplantation pmid:1384185
Pape E et al. Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. 2015 Transplantation pmid:26308424
McCarthy SA et al. The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. 1992 Transplantation pmid:1384186
Bashuda H et al. Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. 1996 Transplantation pmid:8693525
Wang K et al. Transplantation of infantile bladder in rats: an alternative procedure for bladder augmentation. 2001 Transplantation pmid:11213059
Nakajima K et al. Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. 1988 Transplantation pmid:2454521
Gruessner RW et al. Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. 1998 Transplantation pmid:9701258
Pascual J et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. 2010 Transplantation pmid:20335831
Raggi MC et al. Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. 2010 Transplantation pmid:21076373
Sahara H et al. Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. 2010 Transplantation pmid:21076382
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Min SI et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. 2010 Transplantation pmid:21076384
Chan L et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. 2008 Transplantation pmid:18360262
Armitage JM et al. Preliminary experience with FK506 in thoracic transplantation. 1991 Transplantation pmid:1713363
Hricik DE et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. 2002 Transplantation pmid:12151730
Saad ER et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. 2008 Transplantation pmid:18360267
Ueki S et al. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. 2006 Transplantation pmid:17198266
Lorber MI et al. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. 1991 Transplantation pmid:1713364
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Murase N et al. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. 1993 Transplantation pmid:7678353
Herold KC et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. 1993 Transplantation pmid:7678356
Holman MJ et al. FK506-associated thrombotic thrombocytopenic purpura. 1993 Transplantation pmid:7678357
Todo S et al. Small intestinal transplantation in humans with or without the colon. 1994 Transplantation pmid:7512291
Fuchinoue S et al. Kidney transplantation after liver transplantation from the same donor: four cases of successful steroid withdrawal. 2002 Transplantation pmid:11923698
Peduto G et al. Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression. 2000 Transplantation pmid:10919579
Younes BS et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. 2000 Transplantation pmid:10919581
Gruber SA and Doshi MD Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. 2010 Transplantation pmid:20440195
Burger CI et al. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. 2010 Transplantation pmid:20440199
Cherikh WS et al. A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation. 2003 Transplantation pmid:12923430
Wong W et al. 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? 2005 Transplantation pmid:16082321
Krämer BK et al. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. 2012 Transplantation pmid:22858806
Mendez R et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. 2005 Transplantation pmid:16082323
Oku M et al. Hepatocyte growth factor sustains T regulatory cells and prolongs the survival of kidney allografts in major histocompatibility complex-inbred CLAWN-miniature swine. 2012 Transplantation pmid:22158517